Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2(+) breast cancers. We accomplished this by measuring cellular and molecular responses to lapatinib and the AKT inhibitors (AKTi) GSK690693 and GSK2141795 in a panel of 22 H...

Full description

Bibliographic Details
Main Authors: James E Korkola, Eric A Collisson, Laura Heiser, Chris Oates, Nora Bayani, Sleiman Itani, Amanda Esch, Wallace Thompson, Obi L Griffith, Nicholas J Wang, Wen-Lin Kuo, Brian Cooper, Jessica Billig, Safiyyah Ziyad, Jenny L Hung, Lakshmi Jakkula, Heidi Feiler, Yiling Lu, Gordon B Mills, Paul T Spellman, Claire Tomlin, Sach Mukherjee, Joe W Gray
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4504492?pdf=render